Abbott to study blood thinners after treatment with Xience drug-eluting stent

Abbott (NYSE:ABT) said today that it enrolled the first patient in a trial evaluating the short-term use of blood thinning drugs, called dual antiplatelet therapy, after implantation of the company’s Xience everolimus-eluting coronary stent.
The 2,000-patient study is slated to assess if three months of DAPT is non-inferior to the current standard of 12 months for patients at high risk of bleeding.
Get the full story at our sister site, Drug Delivery Business News.
The post Abbott to study blood thinners after treatment with Xience drug-eluting stent appeared first on MassDevice.

Source: Mass Device - July 25, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Drug-Device Combinations Drug-Eluting Stents Wall Street Beat Abbott Source Type: news